Fibroblast growth factor 21 and dietary interventions: what we know and what we need to know next

• Published in: Medical Review Vol. 2; no. 5; pp. 524 - 530
• Main Author: Jin, Tianru
• Format: Journal Article
• Language: English
• Published: De Gruyter 01.10.2022
• Subjects: dietary polyphenol intervention; fibroblast growth factor 21; gut microbiota; protein restriction; Review
• ISSN: 2749-9642; 2097-0773; 2749-9642
• DOI: 10.1515/mr-2022-0019

Dietary interventions include the change of dietary styles, such as fasting and dietary or nutrient restrictions; or the addition of plant-derived compounds (such as polyphenols known as curcumin, resveratrol, or anthocyanin, or other nutraceuticals) into the diet. During the past a few decades, large number of studies have demonstrated therapeutic activities of these dietary interventions on metabolic and other diseases in human subjects or various animal models. Mechanisms underlying those versatile therapeutic activities, however, remain largely unclear. Interestingly, recent studies have shown that fibroblast growth factor 21 (FGF21), a liver-derived hormone or hepatokine, mediates metabolic beneficial effects of certain dietary polyphenols as well as protein restriction. Here I have briefly summarized functions of FGF21, highlighted related dietary interventions, and presented literature discussions on role of FGF21 in mediating function of dietary polyphenol intervention and protein restriction. This is followed by presenting my perspective view, with the involvement of gut microbiota. It is anticipated that further breakthroughs in this field in the near future will facilitate conceptual merge of classical medicine and modern medicine.